908 Devices (NASDAQ:MASS) Director Sells $124,276.46 in Stock

908 Devices Inc. (NASDAQ:MASS) Director Christopher Brown sold 17,578 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $7.07, for a total value of $124,276.46. Following the transaction, the director owned 945,559 shares of the company’s stock, valued at approximately $6,685,102.13. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Stock Performance

Shares of NASDAQ:MASS opened at $7.14 on Monday. The stock has a 50 day moving average of $6.47 and a 200 day moving average of $6.66. The company has a market cap of $266.89 million, a PE ratio of 12.98 and a beta of 0.54. 908 Devices Inc. has a 12-month low of $3.79 and a 12-month high of $9.34.

908 Devices (NASDAQ:MASS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $17.38 million during the quarter, compared to the consensus estimate of $16.19 million. 908 Devices had a negative return on equity of 14.99% and a net margin of 34.68%. Equities research analysts predict that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MASS. AQR Capital Management LLC bought a new position in 908 Devices in the 1st quarter worth approximately $365,000. Geode Capital Management LLC boosted its stake in 908 Devices by 11.7% in the 2nd quarter. Geode Capital Management LLC now owns 658,603 shares of the company’s stock worth $4,697,000 after purchasing an additional 68,764 shares during the period. Rhumbline Advisers boosted its stake in 908 Devices by 5.5% in the 2nd quarter. Rhumbline Advisers now owns 36,416 shares of the company’s stock worth $260,000 after purchasing an additional 1,894 shares during the period. American Century Companies Inc. boosted its stake in 908 Devices by 22.9% in the 2nd quarter. American Century Companies Inc. now owns 56,296 shares of the company’s stock worth $401,000 after purchasing an additional 10,482 shares during the period. Finally, Walleye Capital LLC bought a new position in 908 Devices in the 2nd quarter worth approximately $82,000. 88.06% of the stock is currently owned by institutional investors.

Key Stories Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Neutral Sentiment: SVP Kevin J. McCallion sold 18,580 shares on April 8 at an average $7.05 (proceeds $130,989). The sale was executed under a Rule 10b5‑1 plan and left him with 44,925 shares. Form 4
• Neutral Sentiment: SVP Kevin J. McCallion sold an additional 5,420 shares on April 9 at an average $7.03 (proceeds ~$38.1k), also under a 10b5‑1 plan. He still holds 44,925 shares. Form 4
• Neutral Sentiment: Director Christopher D. Brown sold 17,578 shares on April 10 at $7.07 (proceeds ~$124.3k), under a 10b5‑1 plan; he remains a large holder (~945,559 shares). Form 4
• Neutral Sentiment: Director Christopher D. Brown sold 7,392 shares on April 9 at $7.04 (proceeds ~$52.0k), and 15,030 shares on April 8 at $7.05 (proceeds ~$106.0k); all under a 10b5‑1 plan. Form 4
• Neutral Sentiment: Reported short interest shows 0 shares (as of April 10), implying no measurable short pressure; the short‑interest ratio is effectively 0.0 days based on average volume. Source data flagged anomalous/NaN changes.
• Negative Sentiment: Combined impact: insiders sold ~64,000 shares this week for roughly $450k in proceeds. Even though sales were via 10b5‑1 plans (which mutes informational content), the concentrated volume of insider selling can create near‑term downward pressure or raise investor questions about insider liquidity needs.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research note on Wednesday, January 21st. Wall Street Zen upgraded 908 Devices from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, 908 Devices presently has an average rating of “Hold” and a consensus price target of $12.00.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.